E. Rayburn

发表

Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?

Ruiwen Zhang, E. Rayburn, Ruiwen Zhang, 2008, Drug discovery today.

Wnt/beta-catenin signaling pathway as a novel cancer drug target.

Wei Jiang, Hui Wang, Tong-Chuan He, 2004, Current cancer drug targets.

Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent

Ruiwen Zhang, E. Rayburn, S. Velu, 2010, Marine drugs.

20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action

Hui Wang, Ruiwen Zhang, E. Rayburn, 2008, British Journal of Cancer.

Synthesis and In Vitro Anti-Lung Cancer Activity of Novel 1, 3, 4, 8- Tetrahydropyrrolo (4, 3, 2-de)quinolin-8(1H)-o ne Alkaloid Analogs

Weiqi Wang, Ruiwen Zhang, E. Rayburn, 2009 .

Antisense approaches in drug discovery and development.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2005, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

Antisense-based cancer therapeutics: are we there yet?

Hui Wang, Ruiwen Zhang, E. Rayburn, 2006, Expert opinion on emerging drugs.

FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels

Q. Shi, E. Rayburn, Hui Yao, 2017, Critical reviews in clinical laboratory sciences.

Linkage between Toxicology of Drugs and Metabolism

Ruiwen Zhang, E. Rayburn, 2010 .

Experimental therapy of prostate cancer with novel natural product anti‐cancer ginsenosides

Hui Wang, Ruiwen Zhang, E. Rayburn, 2008, The Prostate.

In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng

Hui Wang, Ruiwen Zhang, E. Rayburn, 2007, Cancer Chemotherapy and Pharmacology.

Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2009, Lung cancer.

Novel immunomodulatory oligonucleotides for cancer therapy

E. Rayburn, 2007 .

Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2009, Cancer letters.

Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng.

E. Rayburn, Y. Zhao, D. Hill, 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

FDA-approved drugs that are spermatotoxic in animals and the utility of animal testing for human risk prediction

E. Rayburn, Jiayi Ding, Liang Gao, 2018, Journal of Assisted Reproduction and Genetics.

Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy

Hui Wang, S. Agrawal, Ruiwen Zhang, 2006, Molecular Cancer Therapeutics.

FDA-approved medications that impair human spermatogenesis

E. Rayburn, Jiayi Ding, X. Shang, 2016, Oncotarget.

Anti-Inflammatory Agents for Cancer Therapy.

Ruiwen Zhang, E. Rayburn, Scharri J. Ezell, 2009, Molecular and cellular pharmacology.

Oncogenes as Novel Targets for Cancer Therapy (Part II)

Hui Wang, Ruiwen Zhang, Zhuo Zhang, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Oncogenes as Novel Targets for Cancer Therapy (Part IV)

Hui Wang, Ruiwen Zhang, Zhuo Zhang, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Chemotherapy and chemosensitization of non–small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9

Hui Wang, S. Agrawal, Ruiwen Zhang, 2006, Molecular Cancer Therapeutics.

Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent

L. Jia, Ruiwen Zhang, E. Rayburn, 2012, Cancer Chemotherapy and Pharmacology.

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

Hui Wang, Hui Wang, Ruiwen Zhang, 2005, Current cancer drug targets.

Oncogenes as Novel Targets for Cancer Therapy (Part III)

Hui Wang, Ruiwen Zhang, Zhuo Zhang, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer

Ruiwen Zhang, E. Rayburn, S. Velu, 2010, Investigational New Drugs.

Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.

Ruiwen Zhang, E. Rayburn, S. Velu, 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

Oncogenes as Novel Targets for Cancer Therapy (Part I)

Hui Wang, Ruiwen Zhang, Zhuo Zhang, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function

W. Wang, D. Chen, Hui Wang, 2007, Oncogene.

RYBP stabilizes p 53 by modulating MDM 2

Hui Wang, Ruiwen Zhang, E. Rayburn, 2013 .

Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases.

Sam W. Lee, Xiao-li Feng, S. Shi, 2007, Lung cancer.

A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action

Ruiwen Zhang, E. Rayburn, S. Velu, 2010, Breast Cancer Research and Treatment.

Extracellular Activity of Cyclic AMP–Dependent Protein Kinase as a Biomarker for Human Cancer Detection: Distribution Characteristics in a Normal Population and Cancer Patients

Hui Wang, Ruiwen Zhang, Zhuo Zhang, 2007, Cancer Epidemiology Biomarkers & Prevention.

In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues

Ruiwen Zhang, E. Rayburn, S. Velu, 2009, Clinical Cancer Research.

KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology

Erwin G. Van Meir, Hui Wang, Ruiwen Zhang, 2012, PloS one.

Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies

Hui Wang, S. Agrawal, Ruiwen Zhang, 2005, Annals of the New York Academy of Sciences.

Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2007, International journal of oncology.

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway

Sudhir Agrawal, Hui Wang, Hui Wang, 2005, Oncogene.

RYBP stabilizes p53 by modulating MDM2

Hui Wang, Deng Chen, Hui Wang, 2009, EMBO reports.

Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2007, International journal of oncology.

Recent advances in validating MDM2 as a cancer target.

Ruiwen Zhang, E. Rayburn, Scharri J. Ezell, 2009, Anti-cancer agents in medicinal chemistry.

Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: Effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy

Hui Wang, Ruiwen Zhang, Zhuo Zhang, 2006, The Prostate.

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2005, Current pharmaceutical design.

In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues

Ruiwen Zhang, E. Rayburn, S. Velu, 2009, Clinical Cancer Research.

Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2007, International journal of oncology.

Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.

Hui Wang, Ruiwen Zhang, E. Rayburn, 2009, Cancer letters.